Blockade of Y177 and Nuclear Translocation of Bcr-Abl Inhibits Proliferation and Promotes Apoptosis in Chronic Myeloid Leukemia Cells

Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes

(2016) Fabio Stagno et al.   Expert Review of Anticancer Therapy

Induction of apoptosis by directing oncogenic Bcr-Abl into the nucleus

(2015) Zheng-Lan Huang et al.   Oncotarget

Inhibition of activated STAT5 in Bcr/Abl expressing leukemia cells with new pimozide derivatives

(2014) Riccardo Rondanin et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

The specific and rapid labeling of cell surface proteins with recombinant FKBP-fused fluorescent proteins

(2014) Xi Zhang et al.   Protein & Cell

PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis

(2013) A Berger et al.   LEUKEMIA

Targeting BCR Tyrosine177 site with novel SH2-DED causes selective leukemia cell death in vitro and in vivo

(2012) Zhi Peng et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Interplay between Kinase Domain Autophosphorylation and F-Actin Binding Domain in Regulating Imatinib Sensitivity and Nuclear Import of BCR-ABL

(2011) Martin Preyer et al.   PLoS One

Controlling subcellular localization to alter function: Sending oncogenic Bcr–Abl to the nucleus causes apoptosis

(2009) Andrew S. Dixon et al.   JOURNAL OF CONTROLLED RELEASE

Quantification of Nuclear Protein Transport using Induced Heterodimerization

(2009) Albert Busch et al.   TRAFFIC

Monitoring disease response to tyrosine kinase inhibitor therapy in CML

(2009) T. P. Hughes et al.   Hematology-American Society of Hematology Education Program

Partial Fanconi Syndrome Induced by Imatinib Therapy: A Novel Cause of Urinary Phosphate Loss

(2008) Helene François et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Cytoplasmic signalling by the c-Abl tyrosine kinase in normal and cancer cells

(2008) Audrey Sirvent et al.   BIOLOGY OF THE CELL

Translation of the Philadelphia chromosome into therapy for CML

(2008) B. J. Druker   BLOOD

Imatinib and leptomycin B are effective in overcoming imatinib-resistance due to Bcr-Abl amplification and clonal evolution but not due to Bcr-Abl kinase domain mutation

(2008) R. K. Kancha et al.   HAEMATOLOGICA

Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia

(2008) L S Steelman et al.   LEUKEMIA